Related Experiment Videos
Pathophysiology of achalasia
1Northwestern University Medical School, Division of Gastroenterology and Hepatology, Searle 10-563, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Current Gastroenterology Reports
|September 12, 2000
Summary
Achalasia, a rare esophageal condition, involves the loss of nitric oxide-producing neurons. Botulinum toxin treatment is supported by evidence of preserved cholinergic innervation in achalasia patients.
Area of Science:
- Gastroenterology
- Neuroscience
- Esophageal Motility Disorders
Background:
- Achalasia affects esophageal myenteric neurons, impacting esophageal motility.
- Cholinergic innervation appears preserved in achalasia, informing treatment strategies.
- Nitric oxide is identified as a key inhibitory neurotransmitter in the gastrointestinal tract.
Purpose of the Study:
- To elucidate the role of nitric oxide in achalasia pathophysiology.
- To explore the rationale behind botulinum toxin treatment for achalasia.
- To review recent findings on the genetic basis of secondary achalasia forms.
Main Methods:
- Review of existing studies on esophageal innervation in achalasia.
- Analysis of the role of nitric oxide in gastrointestinal neurotransmission.
- Examination of genetic and pathogenetic factors in secondary achalasia.
Main Results:
- Absence of nitric oxide-containing neurons in the myenteric plexuses of achalasia patients.
- Experimental inhibition of nitric oxide mimics achalasia manometrically.
- Insights into genetic underpinnings of secondary achalasia, including specific syndromes.
Conclusions:
- Nitric oxide deficiency is central to primary achalasia pathogenesis.
- Understanding neurotransmitter roles supports targeted achalasia therapies.
- Advances in genetics reveal causes for secondary achalasia, aiding diagnosis and management.